Trends and Efficacy in Clostridioides difficile Infection Management at a Polish Clinical Hospital

07 August 2025 : Database Analysis

Jarosław Drobnik

^{ABDEG 1}, Piotr Pobrotyn

^{ADEFG 2*}, Urszula Grata-Borkowska

^{DF 1}, Katarzyna Madziarska

^{DE 3}, Mateusz Baran

^{ABCDEF 4}

DOI: 10.12659/MSM.948254

Med Sci Monit 2025; 31:e948254

Authors information Article notes Copyright and License information

Introduction Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Table 7 Adjusted odds ratios for in-hospital mortality by CDI treatment and patient characteristics (multivariate logistic regression).

Variable	OR	2.5% CI	97.5% CI	P value
Intercept	0.0113	0.0018	0.0727	0.000
Vancomycin only	1.1674	0.4555	2.9919	0.747
Metronidazole + vancomycin	1.9652	0.8885	4.3463	0.095
Rifaximin/Fidaxomicin	1.3273	0.4006	4.3977	0.643
Age (per year)	1.0235	0.9998	1.0477	0.052
Female (vs male)	0.9054	0.5401	1.5179	0.716
Heart failure (yes vs no)	1.2457	0.7012	2.2124	0.458
Antibiotic count (per antibiotic)	1.0453	0.9507	1.1484	0.365

Back to the Article